Exact Sciences Corporation raised revenue guidance for the full year 2023. For the period, the company expects revenue to be in the range of $2.476 billion - $2.486 billion, assuming: Screening revenue of $1.848 billion - $1.853 billion, precision Oncology revenue of $622 million - $627 million, and COVID-19 testing revenue of $6 million compared to previous revenue guidance of $2.441 billion - $2.466 billion, which assumed screening revenue of $1.820 billion - $1.835 billion, precision Oncology revenue of $615 million - $625 million, and COVID-19 testing revenue of $6 million.
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
53.34 USD | -1.22% | -10.32% | -27.90% |
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
-27.90% | 9.84B | |
-4.81% | 3.15B | |
+31.37% | 2.99B | |
-14.73% | 2.15B | |
-14.39% | 1.8B | |
+70.99% | 1.49B | |
+23.17% | 770M | |
-2.18% | 762M | |
+3.18% | 308M | |
+6.63% | 210M |
- Stock Market
- Equities
- EXAS Stock
- News Exact Sciences Corporation
- Exact Sciences Corporation Raises Revenue Guidance for the Full Year 2023